Patients with head and neck cancer are predominantly at risk for malnutrition due to anorexia, sequelae of the treatment that hamper food intake (e.g., xerostomia or dysphagia) and metabolic alterations as a result of inflammation, which can be induced by the tumour or the therapy ([@bib37]; [@bib2]; [@bib31]; [@bib32]). Malnutrition is a subacute or chronic state in which a combination of varying degrees of undernutrition and inflammatory activity has led to a change in body composition and diminished function ([@bib33]). Weight loss is one of the main symptoms of malnutrition.

Weight loss is a frequently observed problem among patients with head and neck cancer ([@bib14]; [@bib10]). Malnutrition before treatment may be seen in as high as 63% of patients, and its prevalence is associated with the location of the tumour ([@bib24]; [@bib1]; [@bib35]; [@bib14]; [@bib4], [@bib5]; [@bib17]). During treatment, many patients develop treatment-related toxicities, of which dysphagia caused by mucositis is one of the most prominent. These acute toxicities result in discomfort and difficulties with eating. During radiotherapy, the prevalence of malnutrition rises to 41--88% ([@bib24]; [@bib35]; [@bib17]). Sequelae of radiation therapy and weight loss may continue for several weeks after completion of radiotherapy ([@bib17]; [@bib20]).

It has been demonstrated that weight loss before treatment is a prognostic indicator for overall survival ([@bib3]; [@bib29]; [@bib36]; [@bib25]; [@bib8]; [@bib1]; [@bib38]; [@bib28]).

As the association between weight loss before or during radiotherapy and disease-specific survival in patients with head and neck cancer is unclear, we set out to investigate this.

Materials and methods
=====================

Study population
----------------

A consecutive cohort of head and neck cancer patients treated by radiotherapy between January 2000 and January 2009 (*n*=1799) was investigated for inclusion in this study. Main inclusion criterion was curative radiotherapy, either as sole treatment (with or without chemotherapy) or postoperatively. Patients younger than 18 years, patients with a tumour of the ear, skin, or oesophagus, and those with previous cancer history were excluded ([Figure 1](#fig1){ref-type="fig"}). The final study population was composed of 1340 patients. This study was approved by the Medical Ethics Committee of the VU University Medical Center Amsterdam.

Radiotherapy
------------

All patients were treated on 6-MV linear accelerators (Varian Medical Systems, Inc., Palo Alto, CA, USA), immobilised in the supine position by the use of individually designed facial masks. From January 2000, conventional three-dimensional conformal radiotherapy was applied until the clinical introduction of parotid gland sparing IMRT in October 2004. In the primary irradiated patients, the tumour and lymph-node metastases were treated with 2 Gy per fraction up to a total dose of 70 Gy. A dose of 46 Gy in daily fractions of 2 Gy (or an equivalent dose of 35 daily fractions of 1.55 Gy) was given to the elective nodal areas. Patients treated with postoperative radiotherapy received 2-Gy daily fractions at the primary site and nodal metastases to a total dose of 56 or 66 Gy, depending on the surgical margin status and the presence of extranodal spread. Again the elective dose was 46 Gy in 2-Gy daily fractions (or an equivalent dose of 28 fractions of 1.8 Gy or 33 fractions of 1.65 Gy). In the case of concomitant chemoradiation, three cycles of cisplatin 100 mg m^−2^ were given on days 1, 22, and 43.

From the start of radiotherapy, patients received dietary counselling to achieve individual nutritional requirements. If nutritional requirements could not be reached by regular food products, then energy-enriched oral nutritional supplements and/or enteral tube feeding by nasogastric tube or percutaneous endoscopic gastrostomy were subscribed.

Data collection
---------------

All data were prospectively collected. At baseline, patient and tumour characteristics were recorded. Weight loss before radiotherapy was recalled by the radiotherapist and, based on the equation (current weight−usual weight)/usual weight × 100%, categorised into four groups: no weight loss, ⩽5% weight loss, \>5--10% weight loss and \>10% weight loss. Body weight was measured at the start of radiotherapy (±7 days) and weekly thereafter until the eighth week, and at 12 weeks after the start of radiotherapy (labelled as 'during radiotherapy\'). Body weight was measured by wearing light indoor clothing and shoes on a digital electronic scale (Seca (Hamburg, Germany), Alpha 770) to the nearest 0.1 kg. Weight was corrected for clothing and shoes by subtracting 2.0 kg for men and 1.3 kg for women ([@bib11]).

Definitions
-----------

Critical weight loss was defined as body weight loss of \>5% from the start of radiotherapy until week 8 or \>7.5% until week 12 according to the international consensus statement ([@bib40]). Because we earlier observed that acute radiotherapy induced toxicity and weight loss arise after 2 weeks of radiotherapy ([@bib17]), the time span for critical weight loss during radiotherapy was expected to be the last month of radiotherapy.

Overall survival was defined as the time elapsed between the start of radiotherapy and the date of death of any cause, or if the patient was still alive, and 5 years after the start of radiotherapy. Disease-specific survival was defined as the time elapsed between the start of radiotherapy and the date of death due to cancer, or if the patient was still alive, and 5 years after the start of radiotherapy. Patients who were lost to follow-up within 5 years were censored at their last date of follow-up. In the analysis of disease-specific survival, deaths due to causes other than head and neck cancer were treated as censored observations at the time of death.

Statistical analysis
--------------------

To test differences in patient, tumour, and treatment characteristics between survivors and non-survivors, *χ*^2^ tests were used regarding gender, tumour location, TNM stage ([@bib9]), baseline WHO performance score, weight loss before radiotherapy, treatment modality, and radiotherapy on the neck nodes, and independent *t* test was used regarding age.

Survival curves were generated using the method of Kaplan--Meier. The log-rank test was used to examine the difference in overall and disease-specific survival between weight loss groups. Cox\'s proportional hazard models were used to build multivariate (i.e., adjusted) models. Relevant factors influencing both weight loss and the survival period were selected *a priori*, based on the literature. Potential confounder variables for the association between weight loss before radiotherapy and overall and disease-specific survival were age, gender, tumour location (oral cavity, oropharynx, nasopharynx, hypopharynx, larynx, nasal cavity and paranasal sinuses, major salivary glands, and unknown primary), TNM stage (I, II, III, and IV), prior head and neck surgery, and baseline WHO performance score (0, 1, and 2/3). For the association between weight loss during radiotherapy and overall and disease-specific survival, we additionally adjusted for weight loss before radiotherapy (no weight loss, ⩽5% weight loss, \>5--10% weight loss, and \>10% weight loss), treatment modality (RT alone, RT+surgery, and RT+chemotherapy±surgery), and radiotherapy on the neck nodes (none, unilateral, and bilateral). We attempted to adjust for comorbidity by the Adult Comorbidity Evaluation-27 (ACE-27) test ([@bib27]), but the scores were available only in patients receiving chemoradiotherapy. Therefore, a subgroup analyses was performed to analyse the effect of comorbidity on the association between weight loss and overall and disease-specific survival.

Interaction between weight loss and gender or age with respect to overall and disease-specific survival was investigated, but both were no effect modifiers. Proportional hazard assumptions for each model was investigated and confirmed by testing the constancy over time of the log-hazard ratio for each model. *P*-values of \<0.05 were considered as statistically significant. Analyses were performed using the SPSS software (version 20.0.0; 2011 IBM Corporation, New York, NY, USA).

Results
=======

The majority of patients (70%) were male. The mean age was 61.4±12.0 years, and ranged from 19 to 96 years. Tumours were mainly located at the larynx and oropharynx. Eighteen percent of patients had stage I tumours, 21% stage II, 18% stage III, whereas 43% had stage IV tumours. Slightly more than half of the patients received a combined modality treatment ([Table 1](#tbl1){ref-type="table"}).

Four-hundred and seventy-one patients (35%) died within 5 years. No significant difference was found between the survivors and the non-survivors regarding gender. There were significant differences between the survivors and the non-survivors regarding age, tumour location, TNM stage, weight loss before radiotherapy, WHO performance score, treatment modality, and radiotherapy on the neck nodes ([Table 1](#tbl1){ref-type="table"}).

Weight loss before radiotherapy
-------------------------------

Before radiotherapy, 70% of patients had no weight loss, 16% had ⩽5% weight loss, 9% had \>5--10% weight loss, and 5% had \>10% weight loss ([Table 1](#tbl1){ref-type="table"}). Five-year overall survival rates for these groups were 71%, 59%, 47%, and 42%, respectively (log rank: *P*\<0.001; [Figure 2](#fig2){ref-type="fig"}). Five-year disease-specific survival rates for these groups were 86%, 86%, 81%, and 71%, respectively (log rank: *P*\<0.001).

The unadjusted Cox\'s regression analysis ([Table 2](#tbl2){ref-type="table"}) showed that weight loss before radiotherapy (of any category) was significantly associated with a worse overall survival. In addition, we found that the two most severe weight loss categories (\>5--10% and \>10% weight loss) were significantly associated with a worse disease-specific survival. After adjustment for all previously mentioned potential confounders, \>10% weight loss before radiotherapy remained significantly associated with a worse overall (HR 1.7; 95% CI 1.2--2.5; *P=*0.002) and disease-specific survival (HR 2.1; 95% CI 1.2--3.5; *P=*0.007) ([Table 2](#tbl2){ref-type="table"}).

In the subgroup of chemoradiotherapy, comorbidity nearly affected the association between weight loss before chemoradiotherapy and overall survival (\>10% weight loss HR 3.3, 95% CI 1.7--6.7, *P=*0.001; \>5--10% weight loss HR 2.3, 95% CI 1.3--4.2, *P=*0.005; ⩽5% weight loss HR 1.8; 95% CI 1.0--3.2; *P=*0.041). Comorbidity was not significantly associated with disease-specific survival.

Weight loss during radiotherapy
-------------------------------

Critical weight loss during radiotherapy was observed in 57% of patients. Mean weight loss during radiotherapy was 4.1 (±4.7) kg, which corresponded to 5.4 (±6.1)% of body weight. On average, patients with critical weight loss lost 9.0 (±4.8)% of their body weight.

Patients with critical weight loss had lower 5-year overall survival rates than patients without critical weight loss during radiotherapy (survival rates: 62% *vs* 70% log rank: *P=*0.01). However, the adjusted association was no longer statistically significant (HR 1.1; 95% CI 0.9--1.4; *P=*0.295) ([Table 3](#tbl3){ref-type="table"}).

The 5-year disease-specific survival rate for patients with critical weight loss was 82%, compared with 89% for patients without critical weight loss (HR 1.7; 95% CI 1.2--2.3; *P=*0.001; [Figure 3](#fig3){ref-type="fig"}). After adjustment for all confounders, disease-specific survival was still significantly worse for patients with critical weight loss during radiotherapy (HR 1.7; 95% CI 1.2--2.4; *P=*0.004) ([Table 3](#tbl3){ref-type="table"}).

In the subgroup of chemoradiotherapy, all patients who died because of head and neck cancer had critical weight loss during therapy. Therefore, no further subgroup analyses were possible.

Patients who were excluded because of missing baseline weight ([Figure 1](#fig1){ref-type="fig"}), had a shorter overall survival time compared with the included patients (log rank: *P=*0.009). Disease-specific survival was not significantly different.

Discussion
==========

Weight loss as a consequence of (chemo)radiotherapy is a common problem in patients with head and neck cancer ([@bib16]). However, little is known about its prognostic effect on disease-specific survival. This study shows that critical weight loss *during* radiotherapy is independently associated with a 1.7 times higher risk of dying of head and neck cancer.

Moreover, this large study demonstrates that weight loss *before* radiotherapy is also independently associated with almost two-fold risk of dying.

The association between pre-treatment weight loss and disease-specific survival has been investigated only once in a subgroup of patients with head and neck cancer ([@bib30]). In that study, weight loss before radiotherapy was an independent predictor for disease-specific survival in patients with cancer of the oropharynx, with a hazard ratio of 2.3. We found comparable results in this mixed group of head and neck cancer patients, and this finding therefore can now be extended to the entire group of patients with head and neck cancer.

Recently, two studies investigated the impact of weight loss during radiotherapy on survival ([@bib26]; [@bib7]). In the study of [@bib26], weight loss during radiotherapy was an independent prognostic factor for locoregional control, but not for survival. [@bib7] found weight loss of ⩾10% during and 1 year after treatment as an independent prognostic factor for disease-free survival (hazard ratio 2.2), but not for overall survival, in patient with cancers of the oral cavity and oropharynx).

Our results are in line with those of Cho *et al* (2013). We examined the association of critical weight loss during radiotherapy and 5-year overall and disease-specific survival. In the unadjusted analysis, we found that critical weight loss during radiotherapy was significantly associated with a worse 5-year overall survival, but this association disappeared after adjusting for other relevant prognostic factors. However, critical weight loss during radiotherapy was an independent prognostic factor for 5-year disease-specific survival.

The observation that patients with critical weight loss during radiotherapy have worse disease-specific survival suggests that treatment is less effective in this patient group. The direct effect of radiotherapy on cancer cell death through irreparable DNA damage is intensified by stimulating an anti-tumour immune response ([@bib39]; [@bib15]; [@bib34]). The poor response to treatment might be due to an impaired immune response as a consequence of insufficient food intake in the malnourished patients. The immune system is highly dependent upon an adequate availability of amino acids ([@bib18]) and specific vitamins, minerals, and trace elements ([@bib41]; [@bib23]). Deficiency of nutrients alters the immune response, even when the deficiency state is relatively mild ([@bib6]). We attempted to link critical weight loss and immunity in our own series. It was previously demonstrated that a severe deficiency of peripheral blood iNKT cells in patients with head and neck cancer was significantly related to poor clinical outcome, suggesting their critical contribution to anti-tumour responses in head and neck cancer patients ([@bib22]). We *post hoc* analysed the relation between weight loss and iNKT cells and found that patients with \>5% weight loss had significantly lower numbers of T cells (722±306 *vs* 1162±580T cells per μl in patients with ⩽5% weight loss, *P=*0.021), and more often a low (\<25th percentile) iNKT cell level compared to patients with ⩽5% weight loss (55% *vs* 15% of patients, *P=*0.004). Although this analysis strengthened our hypothesis, further investigation of the impact of malnutrition on immune response in cancer patients is clearly warranted.

Weight loss during radiotherapy frequently occurs in patients with head and neck cancer. In our study, the prevalence of critical weight loss during and shortly after radiotherapy was 57%. Several different definitions are used to define malnutrition or severe weight loss ([@bib21]). Our cutoff points for critical weight loss during radiotherapy were based on the international consensus statement of the Academy of Nutrition and Dietetics and the American Society for Parenteral and Enteral Nutrition ([@bib40]). Lower or higher cutoff points could probably decrease or increase the hazard ratios.

Although we did not reach weight stabilisation during radiotherapy with our nutritional policy, critical weight loss can be avoided. Several studies in patients with head and neck cancer showed that nutritional therapy can be effective in stabilising body weight during radiotherapy ([@bib13]; [@bib19]). Our results may cautiously suggest that preventing malnutrition by nutritional therapy might exert a positive influence on cause-specific survival. However, intervention studies are needed to answer the important question if prevention of weight loss indeed has an impact on survival.

Most of the previous studies on the association of pre-treatment weight loss and overall survival performed only unadjusted analyses. The drawback of unadjusted survival analyses is that confounders may disturb the relation between weight loss during radiotherapy and survival. Thus, significant differences in the unadjusted analyses may result from other confounding variables, such as tumour location and disease stage. A strength of the present study is that herein adequate adjustment for relevant prognostic factors was possible.

Some limitations of this study should be acknowledged. First, we had to exclude 172 patients (13%) for the analysis of weight loss during radiotherapy, and these patients had a worse overall survival compared with the included patients. It is unknown whether the exclusion of those patients has affected our results, that is, the absence of an association between critical weight loss during radiotherapy and overall survival. Second, the dose distribution of radiotherapy may influence the amount of weight loss during radiotherapy. Given the number of patients we did not delineate organs at risk for weight loss, but we used target volume in general (local *vs* unilateral neck *vs* bilateral neck) as a surrogate for dose to the swallowing structures. In another analysis (unpublished data), we found that this provides useful information with regard to the dose distribution to the most important organs at risk. Third, despite the adjustment for important confounding variables, we were not able to adjust for comorbidity in the entire group of patients. We used the WHO performance score. In the subgroup of patients receiving chemoradiotherapy, results of the ACE-27 test ([@bib27]) were available and used for a subanalysis. In contrast to what we expected, comorbidity did not alter the effect of weight loss on survival. Fourth, just as in other studies, pre-treatment weight loss had to be recalled because patients were newly referred to the hospital. We suppose that patient might have underreported their weight loss, especially patients with the smallest amounts of weight loss who where therefore classified into the reference group. This might have lead to underestimation of the prognostic effects on survival. On the other hand, it has been demonstrated that self-reported weight is a highly sensitive method to define malnutrition ([@bib12]). The weight loss categories in our study had large intervals, so small differences in weight loss estimation would not have lead to other classification. We therefore deem that the results might marginally be influenced by the recall method, and if so, the extent of the association between weight loss before radiotherapy and survival is probably underestimated.

In conclusion, weight loss both before and during radiotherapy are important prognostic indicators for 5-year disease-specific survival in patients with head and neck cancer. Randomised studies into the prognostic effect of nutritional intervention during radiotherapy are needed.
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###### Patient, tumour, and treatment characteristics

                                        **All patients,** ***n*** **(%)**   **Alive,** ***n*** **(%)**   **Dead,** ***n*** **(%)**   ***P*****-value**
  ------------------------------------ ----------------------------------- ---------------------------- --------------------------- -------------------
                                                   1340 (100)                        869 (65)                    471 (35)                     
  **Gender**                                                                                                                        
  Male                                              937 (70)                         595 (64)                    342 (36)                  0.11
  Female                                            403 (30)                         274 (68)                    129 (32)                     
  **Age**                                                                                                                           
  Mean (s.d.)                                       61.4±12.0                       60.0±11.7                    64.1±12.1              **\<0.001**
  **Tumour location**                                                                                                               
  Oral cavity                                       242 (18)                         140 (58)                    102 (42)               **\<0.001**
  Oropharynx                                        310 (23)                         189 (61)                    121 (39)                     
  Nasopharynx                                        47 (4)                          33 (70)                      14 (30)                     
  Hypopharynx                                        74 (6)                          22 (30)                      52 (70)                     
  Larynx                                            436 (33)                         321 (74)                    115 (26)                     
  Nasal cavity and paranasal sinuses                 106 (8)                         77 (73)                      29 (27)                     
  Major salivary glands                              75 (6)                          53 (71)                      22 (29)                     
  Unknown primary                                    50 (4)                          34 (68)                      16 (32)                     
  **TNM stage**                                                                                                                     
  I                                                 232 (18)                         193 (83)                     39 (17)               **\<0.001**
  II                                                269 (21)                         206 (77)                     63 (23)                     
  III                                               232 (18)                         159 (68)                     73 (32)                     
  IV                                                550 (43)                         267 (48)                    283 (52)                     
  **Weight loss before RT**                                                                                                         
  None                                              911 (70)                         642 (71)                    269 (30)               **\<0.001**
  ⩽5%                                               215 (16)                         126 (59)                     89 (41)                     
  \>5--10%                                           111 (9)                         52 (47)                      59 (53)                     
  \>10%                                              69 (5)                          29 (42)                      40 (58)                     
  **WHO performance score**                                                                                                         
  0                                                 399 (38)                         305 (76)                     94 (24)               **\<0.001**
  1                                                 533 (51)                         333 (63)                    200 (37)                     
  2/3                                               116 (11)                         44 (38)                      72 (62)                     
  **Treatment modality**                                                                                                            
  RT alone                                          591 (44)                         403 (68)                    188 (32)                **0.01**
  Surgery+RT                                        485 (36)                         313 (65)                    172 (35)                     
  ChemoRT                                           251 (19)                         143 (57)                    108 (43)                     
  Surgery+ChemoRT                                    13 (1)                          10 (77)                      3 (23)                      
  **RT dose**                                                                                                                       
  Median                                               68                               68                          70                     0.09
  **RT on the neck nodes**                                                                                                          
  No                                                350 (26)                         275 (79)                     75 (21)               **\<0.001**
  Unilateral                                        225 (17)                         162 (72)                     63 (28)                     
  Bilateral                                         762 (57)                         432 (57)                    330 (43)                     

Abbreviations: RT=radiotherapy; s.d.=standard deviation; TNM=tumour, node, metastasis; WHO=world health organisation.

*P*-values \<0.05 are shown in bold. *P*-values were obtained by independent *t-*test or *χ*^2^ tests.

###### Cox regression analyses of the association between weight loss before radiotherapy and 5-year overall and disease-specific survival

                                  **Crude model**    **Adjusted model**[a](#t2-fn3){ref-type="fn"}                   
  ------------------------------- ----------------- ----------------------------------------------- ---------------- -----------
  **Overall survival**                                                                                               
  ⩽5% WL                          1.6 (1.3--2.0)                      **\<0.001**                   1.1 (0.9--1.4)      0.388
  \>5--10% WL                     2.3 (1.7--3.0)                      **\<0.001**                   1.4 (1.2--1.9)    **0.026**
  \>10% WL                        3.1 (2.2--4.3)                      **\<0.001**                   1.7 (1.2--2.5)    **0.002**
  **Disease-specific survival**                                                                                      
  ⩽5% WL                          1.1 (0.8--1.7)                         0.570                      0.9 (0.6--1.4)      0.647
  \>5--10% WL                     1.7 (1.1--2.7)                       **0.021**                    1.3 (0.8--2.1)      0.333
  \>10% WL                        3.3 (2.1--5.3)                      **\<0.001**                   2.1 (1.2--3.5)    **0.007**

Abbreviations: CI=confidence interval; HR=hazard ratio; WL=weight loss; TNM=tumour, node, metastasis; WHO=world health organisation.

*P*-values \<0.05 are shown in bold.

Adjusted for age, gender, tumour location, TNM stage, prior head and neck surgery, and WHO performance score.

###### Cox regression analyses of the association between critical weight loss during radiotherapy and 5-year overall and disease-specific survival

                                                         **Crude model**   **Adjusted model**[a](#t3-fn3){ref-type="fn"}                     
  ------------------------------------------------------ ----------------- ----------------------------------------------- ----------------- -------------------
                                                         **HR (95% CI)**   ***P*****-value**                               **HR (95% CI)**   ***P*****-value**
  Overall survival[b](#t3-fn4){ref-type="fn"}            1.3 (1.1--1.6)    **0.010**                                       1.1 (0.9--1.4)    0.295
  Disease-specific survival[b](#t3-fn4){ref-type="fn"}   1.7 (1.2--2.3)    **0.001**                                       1.7 (1.2--2.4)    **0.004**

Abbreviations: CI=confidence interval; HR=hazard ratio; TNM, tumour, node, metastasis; WHO=world health organisation.

*P*-values \<0.05 are shown in bold.

Adjusted for age, gender, tumour location, TNM stage, WHO performance score, weight loss before radiotherapy, radiotherapy on the neck nodes and treatment modality.

No critical weight loss *vs* critical weight loss (\>5% weight loss from the start of radiotherapy until week 8 and/or \>7.5% until week 12).
